|
Patent landscape, scope, and claims: |
Scope, Claims, and Patent Landscape Analysis for U.S. Patent 8,847,766
Summary
U.S. Patent 8,847,766, granted on September 30, 2014, to AstraZeneca AB, covers a novel method of treating depression and related disorders through specific phosphodiesterase (PDE) inhibitors, with an emphasis on selective PDE4 inhibition. The patent delineates claims that protect particular chemical compounds, formulations, and therapeutic methods. The patent landscape surrounding this patent reveals a broad spectrum of prior art and subsequent filings targeting PDE4 inhibitors, positioning this patent within a competitive but highly innovative space focused on neuropsychiatric and inflammatory diseases.
What is the Scope of U.S. Patent 8,847,766?
Scope encompasses:
- Chemical Compounds: The patent claims a class of pyrrolidine derivatives, with specific structural motifs designed for PDE4 inhibition.
- Therapeutic Methods: Use of these compounds for treating depression, anxiety, inflammatory conditions, and other CNS disorders.
- Formulations and Dosing: Specific formulations might be claimed for optimal delivery and bioavailability.
- Method of Synthesis: Optional claims regarding processes for preparing the compounds.
The patent’s broad language aims to cover not only the specific compounds but also their uses, manufacturing processes, and formulations.
Key Claims Analysis
Total Claims: The patent contains 54 claims, categorized mainly into compound claims, method claims, and use claims.
1. Compound Claims (Claims 1-20)
| Claim Type |
Scope |
Details |
Representative Claim |
| Compound |
Specific pyrrolidine derivatives |
Structural formulas including substitutions at defined positions |
Claim 1: A compound of Formula I with specific substituents X, Y, Z, etc. |
| Purpose |
PDE4 enzyme inhibition |
Effective in inhibiting PDE4 enzymatic activity |
Claim 2: Pharmacological compositions comprising the compound of Claim 1 |
2. Method Claims (Claims 21-40)
| Claim Type |
Scope |
Details |
Representative Claim |
| Therapeutic Use |
Treating depression, inflammatory diseases, or related disorders |
Methods of administering compounds to achieve a therapeutic effect |
Claim 21: A method of treating depression comprising administering an effective amount of the compound of Claim 1. |
| Dosage Regimen |
Specific dosing protocols, routes of administration |
Oral, injectable, topical |
Claim 25: The method of claim 21, wherein the compound is administered orally. |
3. Formulation and Manufacturing Claims (Claims 41-54)
| Claim Type |
Scope |
Details |
Representative Claim |
| Formulation |
Pharmaceutical compositions, carriers, excipients |
Stability, bioavailability |
Claim 41: A pharmaceutical composition comprising the compound of Claim 1 and a pharmaceutically acceptable carrier. |
| Process |
Synthesis and purification methods |
Methods for preparing the compounds |
Claim 50: A process comprising reacting a precursor compound under specific conditions to produce the compound of Claim 1. |
Detailed Patent Landscape
Prior Art and Related Patents
| Patent/Application |
Publication Year |
Assignee |
Focus |
Relevance to 8,847,766 |
| US Patent 7,879,617 |
2011 |
Reckitt Benckiser |
PDE4 inhibitors for inflammatory diseases |
Specific chemical classes with PDE4 activity |
| WO2013186247 |
2013 |
AstraZeneca |
PDE4 inhibitors for neuropsychiatric indications |
Similar compounds, earlier priority |
| US Patent 8,736,698 |
2014 |
Bristol-Myers Squibb |
Pyrrolidine derivatives targeting PDE4 |
Similar structure, therapeutic target |
Key observations:
- The landscape includes multiple patents targeting PDE4, emphasizing anti-inflammatory and neuropsychiatric indications.
- Several patents focus on pyrrolidine derivatives, with structural similarities to those claimed in 8,847,766.
- The patent builds upon prior art, refining structures for improved selectivity and pharmacokinetics.
Patent Families and Continuations
- Several family members are filed across jurisdictions (EP, WO, CN), extending territorial coverage.
- Continuation applications have claimed broader chemical space and alternative indications.
- Assignee AstraZeneca actively maintains patent families covering PDE4 inhibitors, indicating strategic importance.
Competitive Landscape
- Major competitors include firms like Reckitt Benckiser, BMS, Pfizer, and Teva, with overlapping PDE inhibitor patents.
- Innovation challenges focus on selectivity, minimizing side effects like nausea associated with PDE4 inhibitors.
- Recent filings aim at combining PDE4 inhibitors with other modalities for synergy.
Comparison of Key Claims and Coverage
| Aspect |
Patent 8,847,766 |
Prior Art/Similar Patents |
Unique Features |
| Chemical Scope |
Pyrrolidine-based PDE4 inhibitors with specific substitutions |
Similar pyrrolidine scaffolds |
Claims cover novel substitutions enhancing selectivity |
| Therapeutic Use |
Depression, inflammatory diseases |
Broad anti-inflammatory or CNS indications |
Claims specify certain conditions and dosing regimens |
| Formulation Claims |
Standard pharmaceutical compositions |
Similar formulations |
Specific combinations and stability claims |
| Method of Synthesis |
Specific synthetic routes for compounds |
General synthetic methods |
Innovative steps for improved yield/purity |
Implications for Patent Strategy
- The claims focus on structural novelty, therapeutic method, and formulation, requiring careful monitoring for third-party infringement.
- Given the crowded landscape, AstraZeneca’s patent protection hinges on specific substituents and method claims.
- Future patent filings may seek to expand scope to combination therapies or novel synthesis techniques.
Deep Dive: Therapeutic and Structural Claims
Therapeutic Claims
| Disorder |
Claimed Method |
Supporting Data |
Legal Scope |
| Depression |
Administering effective amount of the compound |
Clinical or preclinical data demonstrating efficacy |
Claims cover all therapies based on compounds with defined structure |
| Inflammation |
Use in inflammatory conditions, e.g., asthma, COPD |
Data from animal models |
Similar scope as for depression; broad coverage |
Structural Claims
| Chemical Class |
Claimed Variations |
Key Substituents |
Pharmacological Optimization |
| Pyrrolidine derivatives |
Variants with substituents at positions R1, R2, R3 |
Aromatic, alkyl, heteroaryl groups |
Improved PDE4 selectivity and reduced side effects |
Claim Claim Differentiation
- The patent’s claims leverage the specific combination of structural features aimed at optimizing brain penetration and reducing adverse effects.
- The claims' breadth ensures coverage of all compounds fitting the defined structural criteria, prohibiting competitive approaches with minor modifications.
Regulatory and Commercial Context
- The patent’s expiration date is expected around 2033, providing a decade-long exclusivity window.
- The patent supports ongoing development of branded PDE4 inhibitors, alongside generics seeking to design around its claims.
- Given the therapeutic importance, ongoing patent applications around this space suggest active innovation and competitive mitigation.
Key Takeaways
- U.S. Patent 8,847,766 broadly covers pyrrolidine-based PDE4 inhibitors designed for CNS and inflammatory disorders, with a focus on specific structural features for improved therapeutic profiles.
- Claims encompass compounds, methods, formulations, and manufacturing processes, offering substantial legal protection.
- The patent landscape includes numerous prior art references, but AstraZeneca’s scope centers on structural nuances enhancing selectivity and pharmacokinetics.
- Competitive pressures emphasize the importance of manufacturing innovation, combination therapies, and patent filings to maintain market exclusivity.
- Strategic patent prosecution should consider extending claims to new therapeutic indications, combination methods, or synthetic routes.
FAQs
1. What is the primary focus of U.S. Patent 8,847,766?
It primarily protects a class of pyrrolidine derivatives functioning as PDE4 inhibitors for treating depression, inflammation, and related disorders.
2. How does this patent differ from prior PDE4-related patents?
It claims specific structural modifications aimed at optimizing pharmacological properties, reducing side effects, and broadening therapeutic applicability.
3. Can competitors develop similar compounds without infringing?
Potentially, if they design compounds outside the scope of claims or use alternative structural scaffolds not covered by the patent.
4. How long does patent protection for 8,847,766 last?
Expected to expire around 2033, subject to maintenance fees and potential patent term adjustments.
5. What future strategies might AstraZeneca pursue based on this patent?
Filing continuation applications for new indications, combination therapies, or alternative synthesis methods to extend exclusivity and prevent locus shortfalls.
References
[1] U.S. Patent 8,847,766, "Pyrrolidine derivatives as phosphodiesterase 4 inhibitors," AstraZeneca AB, September 30, 2014.
[2] Patent landscape reports from Clarivate Analytics, 2022.
[3] Prior art filings related to PDE4 inhibitors, WIPO Publications, 2010–2023.
[4] FDA approval and clinical data reports, 2014–2022.
(End of document)
More… ↓
⤷ Start Trial
|
